Morningside

Xealth Inc. operates a digital health prescribing platform that allows clinicians to integrate, prescribe, and monitor digital health tools directly from electronic health record (EHR) workflows. Founded in 2016 and based in Seattle, Washington, the platform facilitates patient engagement by enabling care teams to order appropriate digital health tools and programs, which can be sent to patients via email or patient portals. In addition to managing digital health prescriptions, the platform supports patient education and offers non-clinical services such as ride shares and food delivery. This comprehensive approach allows clinicians to monitor patient activity and engagement, ultimately enhancing the overall effectiveness of digital health initiatives within healthcare systems.

Accro Bioscience is a biotechnology company that develops innovative small molecule drugs aimed at treating inflammatory and autoimmune diseases, as well as cancer. The company specializes in researching the molecular mechanisms of regulated cell death, including necroptosis, pyroptosis, and ferroptosis. By understanding these processes and their roles in disease pathogenesis, Accro Bioscience seeks to enhance current therapeutic standards in targeted disease areas, contributing to advancements in treatment options for patients.

League is a technology company that focuses on transforming healthcare through a digital platform designed to enhance consumer experiences. It offers a healthcare consumer experience platform that facilitates personalized digital health solutions, enabling healthcare providers, partners, and employers to improve service delivery. By providing the necessary infrastructure for digital transformation, League allows these stakeholders to engage with consumers effectively and efficiently, helping them manage costs and improve health outcomes. The platform is aimed at making healthcare more accessible and tailored to individual needs, ultimately driving measurable results in the industry.

SimpliFed is a telehealth company founded in 2020 that offers virtual breastfeeding support to new and pregnant parents. The company focuses on providing accessible care during the peri and postnatal periods, addressing the challenges faced by parents, including sleep deprivation and concerns about infant nutrition. SimpliFed specializes in lactation and baby feeding support, as well as monitoring high-risk conditions such as hypertension and gestational diabetes. Through secure online and video-based connections, patients can engage with care navigators who guide them through their maternal care journey, helping them obtain quick answers to their questions about their infants' dietary needs.

AdvanCell is a clinical-stage radiopharmaceutical company focused on developing innovative cancer therapies. The company specializes in alpha-emitting isotopes, specifically 212Pb, which are attached to molecules that target tumors directly. This approach allows for the delivery of cytotoxic radiation at the molecular level, addressing significant challenges in targeted alpha therapy regarding supply reliability and scalability. By providing safe and effective treatments for various forms of cancer, AdvanCell aims to establish its therapies as a standard of care in oncology.

Geneoscopy, LLC, based in Saint Louis, Missouri, specializes in developing non-invasive diagnostic tests aimed at preventing, detecting, and guiding treatment for gastrointestinal diseases, particularly colorectal cancer. Founded in 2015, the company utilizes a proprietary platform that extracts stool-derived eukaryotic RNA (seRNA) to create a multi-target RNA biomarker panel. This innovative approach allows for the identification of colorectal cancer by capturing the effects of DNA mutations associated with the disease. Geneoscopy's technology not only enhances screening compliance but also facilitates the early detection of colorectal neoplasms, ultimately aiming to reduce morbidity and mortality linked to colorectal cancer. The company is also exploring additional applications of its technology for related gastrointestinal conditions.

Alentis Therapeutics AG is a clinical-stage biopharmaceutical company based in Basel, Switzerland, focused on developing innovative therapies for advanced liver diseases, including liver fibrosis, cirrhosis, and liver cancer. Established in 2019, Alentis is recognized for its pioneering work in targeting CLDN1+ cancers through the use of anti-CLDN1 antibody-drug conjugates and other therapeutic modalities. The company's research platform incorporates clinically relevant read-outs and single-cell RNA sequencing of patient liver tissues, which aids in understanding and treating fibrotic diseases. Alentis aims to modify and reverse disease progression, ultimately addressing significant health challenges associated with liver-related conditions.

CairnSurgical is focused on creating innovative patient-specific tools designed to enhance the precision and accuracy of surgical interventions for cancer patients. The company utilizes patient imaging data combined with advanced 3D printing technologies to develop its image guidance devices. By providing healthcare professionals with tailored solutions, CairnSurgical aims to improve surgical outcomes and ensure that interventions are more effectively aligned with the unique anatomical features of each patient.

Kappa Pay is a fintech platform that utilizes blockchain technology to streamline payment processes for both local and cross-border transactions. The company aims to provide an affordable and reliable solution for individuals and merchants, facilitating seamless payments that resemble the simplicity of sending a message. By focusing on removing friction and barriers in financial transactions, Kappa enables users to send and receive money globally with higher transaction limits, enhancing the overall efficiency of the payment experience.

ENYO Pharma SA is a clinical-stage biopharmaceutical company based in Lyon, France, that focuses on the discovery and development of innovative treatments for acute and chronic viral infections. Established in 2014 by a team of scientists from the Infectiology Research Center, the company utilizes a proprietary platform to identify intracellular therapeutic targets and develop small molecule therapeutics. ENYO Pharma's research primarily targets significant human infecting viruses, with current programs aimed at treating chronic hepatitis B and severe influenza. The company's pipeline includes a lead compound, EYP001, which modulates FXR to reduce the cccDNA reservoir and inhibit the expression of viral proteins, along with EYP002, which is in preclinical studies. With an emphasis on addressing unmet medical needs in infectious diseases and metabolic disorders, ENYO Pharma has established collaborations with prominent research institutions to enhance its drug development efforts.

Suvera Ltd, established in 2019 and based in London, United Kingdom, has developed a virtual care follow-up application aimed at enhancing primary care for patients with long-term conditions. The platform allows general practices to manage patients remotely, focusing on conditions such as hypertension, diabetes, asthma, COPD, depression, and anxiety. By enabling patients to engage in their care through their phones, Suvera aims to improve health outcomes, reduce hospital admissions, and minimize the need for in-person doctor appointments, ultimately allowing patients to spend more time in good health and reach their personal health milestones.

Pelicargo operates an air cargo marketplace platform designed to simplify the process of air freight shopping. The company connects freight forwarders with a broad network of airline partners, allowing for efficient matching of cargo to available flight options. By automating the procurement process, Pelicargo facilitates instant access to competitive air freight rates and accurate quotations. This streamlined approach enables transporters to easily book air freight services, thereby enhancing logistical efficiency and reducing the time spent on repetitive tasks.

FireCyte Therapeutics is focused on developing innovative treatments for progressive neurodegenerative eye diseases by targeting the roles of microglia and neuroinflammation. The company utilizes novel protein constructs designed to interact with both microglia and neurons, aiming to reduce harmful neuroinflammatory processes while promoting neuroprotection. This approach addresses significant unmet medical needs in conditions such as glaucoma and age-related macular degeneration, providing healthcare professionals with new therapeutic options for managing these challenging diseases.

Jitjatjo is a workforce management platform and talent marketplace that addresses talent acquisition and human capital resourcing challenges, particularly in the Leisure & Hospitality and Retail sectors. The company provides on-demand staffing solutions through its contingent labor marketplace, Ondemand, and offers a SaaS platform called Network that helps enterprise clients enhance their labor models. By utilizing artificial intelligence and empathic intelligence, Jitjatjo specializes in payroll and hiring, enabling organizations to fulfill personalized and immediate staffing requirements effectively. The company's vision is to transform the way people work, thereby maximizing productivity and empowering individual lifestyle choices, while its mission centers on creating opportunities for the next-generation workforce.

Angitia Biopharmaceuticals is a global biotechnology company dedicated to discovering and developing innovative therapeutics for serious musculoskeletal diseases. The company focuses on researching and creating breakthrough therapies aimed at treating conditions affecting bones, muscles, and joints. By prioritizing the development of novel drugs, Angitia Biopharmaceuticals aims to improve patient outcomes and facilitate recovery from severe musculoskeletal ailments.

Epigenic Therapeutics is a biotechnology company focused on developing gene editing therapies that leverage gene-silencing technology to address a range of diseases. The firm specializes in epigenome editing, aiming to regulate various conditions, including those related to ophthalmology, neurodegeneration, metabolism, and rare diseases. By creating innovative treatments, Epigenic Therapeutics seeks to offer effective solutions for patients suffering from chronic and severe health issues.

GaeaStar is a company focused on creating environmentally friendly products aimed at reducing waste and pollution associated with single-use items. The company has developed patented technology to produce uniquely thin clay cups using locally sourced, natural materials. This innovative approach combines the convenience of single-use products with the benefits of reusability, addressing the pressing need for circular alternatives in a market where over 500 billion single-use cups are consumed annually, with less than 1% recycled. By employing geo-neutral materials and efficient additive manufacturing techniques, GaeaStar aims to offer products that not only perform well and are cost-effective but also promote conscious consumption and sustainability.

Cognito Therapeutics, established in 2016 and headquartered in Newton Centre, Massachusetts, with additional locations in San Francisco and Boston, is a clinical-stage neurotechnology company. It specializes in developing non-invasive, device-based therapies to treat neurodegenerative diseases, with a primary focus on Alzheimer's disease. The company's innovative approach involves using induced brain wave oscillations to reactivate the immune system in the brain, aiming to reduce typical disease hallmarks such as amyloid plaques and tau tangles. Co-founded by MIT professors Li-Huei Tsai and Ed Boyden, Cognito's lead therapy is currently in a pivotal study for Alzheimer's, and has been recognized as a Breakthrough Device by the FDA.

PhagePharm is a company focused on the industrialization of bacteriophages, specifically developing antibiotics and phage products for the animal breeding industry. The organization creates a range of effective disease immunization solutions aimed at enhancing the health of animals and supporting the growth of the animal breeding and agricultural sectors. By providing innovative health products, PhagePharm aims to improve overall animal health and productivity within these industries.

LumiraDx Ltd, incorporated in 2016 and based in London, United Kingdom, is a next-generation point-of-care diagnostics company. It specializes in manufacturing an innovative diagnostic platform that provides a wide range of tests with lab-comparable performance. LumiraDx aims to transform healthcare by offering solutions that facilitate integrated, patient-centered care, enhancing safety, efficiency, and health outcomes. The company's diagnostic system includes a portable instrument, low-cost test strips, and seamless digital connectivity, making diagnostic-led care simpler and more accessible. LumiraDx operates in multiple countries, including the United States, Italy, Germany, and Sweden, with a significant portion of its revenue generated from the U.S. market.

Evonetix Ltd is a biotechnology company based in Little Chesterford, United Kingdom, established in 2015. The company focuses on developing innovative technology for the parallel synthesis of DNA on silicon arrays, thereby advancing the field of synthetic biology. By employing novel techniques, Evonetix aims to synthesize DNA with higher accuracy and scale, which enhances accessibility for researchers. This platform enables scientists to utilize synthetic biology on a previously unattainable scale, fundamentally changing how DNA is accessed, produced, and utilized for gene synthesis. The engineering team at Evonetix boasts extensive experience in creating high-integrity automated systems, bringing together a diverse range of expertise from various scientific and engineering disciplines to support its mission.

Zhide New Energy is a developer of approaches to synthetize new silicon anode materials. They focuses on silicon technology that can be applied to produce new materials. They also produce battery with high energy density and low cost. They manufactures battery for 3C and EV. They provide batteries for fields, such as electric vehicles, consumer electronics, house power storage, and wearable devices.

Mevox translates molecular characterization, design, and engineering into conformationally precise and optimized protein antigens.

WiseConn is focused on addressing the challenges of resource decline by developing technology for the measurement and control of water and other fluids across various sectors, including agriculture, mining, and hydrology. The company offers an agriculture management platform that provides a field monitoring and control network. This platform features wireless hardware installed in the field, complemented by software accessible via the internet. Users can obtain real-time information on fertigation, climate conditions, soil moisture, and plant health, enabling them to monitor, control, and automate irrigation systems effectively. This innovative approach aims to reduce water consumption, enhance operational efficiency, and support informed decision-making for field managers.

Resilience Lab is a company focused on enhancing the delivery of mental health care through innovative clinical services and therapy centers. It aims to expand access to mental health resources by offering a range of services, including individual, couple, and family therapy, as well as parenting support, nutrition therapy, and weight management. By providing personalized and high-quality care, Resilience Lab seeks to empower individuals and families to achieve sustainable mental and physical well-being. The company emphasizes a collaborative approach among clinicians to ensure that clients receive comprehensive support tailored to their unique needs.

CollegeVine is a company based in Cambridge, Massachusetts, founded in 2013, that specializes in providing a range of educational services, including mentorship, college application guidance, essay assistance, tutoring, and test preparation consulting. Formerly known as Admissions Hero LLC, the company rebranded in 2016 to reflect its broader mission. CollegeVine also focuses on integrating artificial intelligence into the higher education sector, offering AI agents designed to streamline administrative processes and enhance recruitment efforts for colleges and universities. By leveraging proprietary data and a network of high school students, CollegeVine aims to improve efficiency, reduce costs, and transform the overall student experience, addressing the projected financial challenges within the higher education landscape. Over 100 universities have adopted CollegeVine's AI solutions to optimize their administrative workflows.

Valitor, Inc. is a biotechnology company founded in 2010 and based in Berkeley, California. The company specializes in developing advanced, protein-based drugs through innovative methods that enhance therapeutic proteins' pharmacokinetics, target specificity, and bioactivity. Valitor's technology platform is versatile, enabling improvements in the pharmacological properties of various existing and emerging protein drugs. The company has established development pipelines in dermatology, ophthalmology, and orthopedics, showcasing its capabilities in creating novel drug products tailored to specific medical needs.

Kezar Life Sciences, Inc. is a clinical-stage biotechnology company specializing in the discovery and development of small molecule therapeutics aimed at addressing unmet medical needs in autoimmunity and cancer. The company's lead candidate, KZR-616, is a selective immunoproteasome inhibitor currently undergoing Phase 2 clinical trials for various autoimmune conditions, including lupus nephritis and autoimmune hemolytic anemia, as well as Phase 1b/2 trials in systemic lupus erythematosus. In addition to KZR-616, the company is developing KZR-TBD, which targets both oncology and autoimmune disorders. Founded in 2015 and based in South San Francisco, California, Kezar Life Sciences leverages insights from protein homeostasis to advance its drug discovery efforts.

Kappa Pay is a fintech platform that utilizes blockchain technology to streamline payment processes for both local and cross-border transactions. The company aims to provide an affordable and reliable solution for individuals and merchants, facilitating seamless payments that resemble the simplicity of sending a message. By focusing on removing friction and barriers in financial transactions, Kappa enables users to send and receive money globally with higher transaction limits, enhancing the overall efficiency of the payment experience.

AdvanCell is a clinical-stage radiopharmaceutical company focused on developing innovative cancer therapies. The company specializes in alpha-emitting isotopes, specifically 212Pb, which are attached to molecules that target tumors directly. This approach allows for the delivery of cytotoxic radiation at the molecular level, addressing significant challenges in targeted alpha therapy regarding supply reliability and scalability. By providing safe and effective treatments for various forms of cancer, AdvanCell aims to establish its therapies as a standard of care in oncology.

GreenLight Biosciences, Inc. is a biotechnology company that specializes in developing RNA-based solutions for agricultural and pharmaceutical applications. Headquartered in Medford, Massachusetts, with an additional facility in North Carolina, the company focuses on producing high-quality RNA quickly and cost-effectively. GreenLight's technology platform facilitates the biological conversion of renewable substrates into valuable products, including chemicals and fuels. The company is actively involved in advancing vaccine development, particularly mRNA-based candidates aimed at preventing diseases such as SARS-CoV-2. Additionally, GreenLight engages in crop management and plant protection initiatives, contributing to sustainable agricultural practices and supporting the health of pollinators. Through its innovative approaches, GreenLight Biosciences aims to address global challenges in food security and public health.

Epigenic Therapeutics is a biotechnology company focused on developing gene editing therapies that leverage gene-silencing technology to address a range of diseases. The firm specializes in epigenome editing, aiming to regulate various conditions, including those related to ophthalmology, neurodegeneration, metabolism, and rare diseases. By creating innovative treatments, Epigenic Therapeutics seeks to offer effective solutions for patients suffering from chronic and severe health issues.

Bevi is a manufacturer of smart water dispensers designed for offices and commercial spaces. Their innovative product offers customizable flavors created from filtered tap water and natural ingredients, allowing users to make personalized drinks. Bevi's dispensers provide nutritional information and enable users to track their environmental impact, promoting eco-friendly hydration. By eliminating the need for bottled beverages, Bevi aims to reduce waste associated with production, shipping, and disposal. The company envisions a future in which their platform transforms beverage delivery by utilizing the municipal water supply.

Airspace Link, Inc. is a company that specializes in managing local airspace for drones through its enterprise software-as-a-service platform. Founded in 2018 and based in Plymouth, Michigan, the company offers a range of tools designed for various stakeholders. Its AirRegistry platform facilitates the approval of automated drone package deliveries, while AirInspect provides tools for inspecting and approving registered drone delivery sites. AirHub aids in the creation of a comprehensive drone delivery network by mapping flight corridors, no-fly zones, and delivery locations. Additionally, AirLink enables state and local governments to share their regulated airspace with drone delivery services. By digitizing local airspace, Airspace Link supports safe recreational and commercial drone operations, fostering innovation and empowerment among businesses and citizens.

Eko Health is a leading digital health company advancing how healthcare professionals detect and monitor heart and lung disease with its portfolio of digital stethoscopes, patient and provider software, and AI-powered analysis. Its FDA-cleared platform is used by hundreds of thousands of healthcare professionals worldwide, allowing them to detect earlier and with higher accuracy, diagnose with more confidence, manage treatment effectively, and ultimately give their patients the best care possible. Eko Health is headquartered in Emeryville, California, with over $125 million in funding from Highland Capital Partners, Questa Capital, Artis Ventures, DigiTx Partners, NTTVC, Morningside Technology Ventures Limited, Mayo Clinic, Sutter Health, and others. For more information visit www.ekohealth.com.

Adiso Therapeutics is a biopharmaceutical company focused on developing innovative treatments for inflammatory diseases. The company aims to address the limitations of current treatment options, which often fail to halt disease progression or pose significant safety risks to patients. Adiso is advancing a unique pipeline of therapies that includes small molecules and single-strain live biotherapeutic products, both designed with novel mechanisms of action. By creating these new therapies, Adiso seeks to improve patient outcomes and provide effective solutions for those suffering from debilitating inflammatory conditions.

Cydar Medical is a technology company that specializes in developing computer vision software for real-time automated 3D overlays during X-ray guided procedures. This innovative approach allows clinicians to focus more on patient care rather than managing display adjustments. Cydar's platform leverages cloud supercomputing to deliver high-performance overlay updates, enhancing the quality of care provided to patients. Additionally, the company offers a cloud-based clinical platform that facilitates access to clinical applications and data insights, supporting hospitals in optimizing their operational capabilities and improving patient outcomes.

Curve Health, Inc. is an innovative online platform focused on enhancing senior care by integrating telemedicine, health information exchange, predictive analytics, and smart billing. Founded in 2020 and based in New York, the platform facilitates remote care for patients in skilled nursing facilities, at home, and in emergency situations, significantly reducing the need for patient transfers to emergency departments. By streamlining communication and operations between healthcare providers and post-acute facilities, Curve Health improves care quality and patient outcomes while optimizing resource allocation. The platform also accelerates reimbursement processes and automates documentation, making it a comprehensive solution for modern healthcare challenges in senior care.

GreenLight Biosciences, Inc. is a biotechnology company that specializes in developing RNA-based solutions for agricultural and pharmaceutical applications. Headquartered in Medford, Massachusetts, with an additional facility in North Carolina, the company focuses on producing high-quality RNA quickly and cost-effectively. GreenLight's technology platform facilitates the biological conversion of renewable substrates into valuable products, including chemicals and fuels. The company is actively involved in advancing vaccine development, particularly mRNA-based candidates aimed at preventing diseases such as SARS-CoV-2. Additionally, GreenLight engages in crop management and plant protection initiatives, contributing to sustainable agricultural practices and supporting the health of pollinators. Through its innovative approaches, GreenLight Biosciences aims to address global challenges in food security and public health.

Casana is a healthcare technology company based in Rochester, New York, that specializes in in-home cardiac health monitoring solutions. Its flagship product, the Heart Seat, is a cloud-connected toilet seat designed to allow patients to effortlessly monitor critical health metrics such as heart rate, blood pressure, blood oxygenation, and cardiac output from the comfort of their homes. The Heart Seat integrates three key sensors: a single-lead ECG for measuring the heart's electrical activity, PPG sensors that assess blood volume, and BCG sensors that track the mechanical activity of the heart. This innovative device aims to assist medical teams in managing chronic conditions by providing continuous, reliable health data outside traditional healthcare settings. Casana's technology is focused on fostering proactive health management and improving patient outcomes.

Big Health is a digital therapeutics company headquartered in London, United Kingdom, that specializes in developing and marketing innovative behavioral health programs. The company's flagship product, Sleepio, is a digital sleep improvement program that employs Cognitive Behavioral Therapy techniques to address and personalize sleep disorders. By offering a fully automated healthcare portal, Big Health delivers highly personalized digital therapeutics and behavioral programs aimed at tackling various mental health issues. Their approach combines medical consultation with user-friendly technology, enabling individuals to effectively manage and overcome sleep-related disorders in an efficient manner.

Virtue Diagnostics (Suzhou) Co., Ltd. is an in vitro diagnostic company established in 2019 and headquartered in Suzhou, China, with a research and development office in Singapore. The company specializes in developing advanced diagnostic technologies aimed at infectious diseases, cancer, and chronic diseases. Its offerings include clinical mass spectrometry, multiplex immunohistochemistry for pathology-based cancer detection, and a molecular and immunoassay platform. Through these technologies, Virtue Diagnostics aims to enhance disease detection and management, contributing to improved healthcare outcomes.

Almond Fintech, based in Boston and Singapore, operates a blockchain-based funds transfer infrastructure that connects numerous financial institutions worldwide. The company focuses on facilitating cross-border payments and remittances, allowing millions of users to send money globally through their existing financial services. Almond Fintech offers a suite of APIs that support peer-to-peer transfers and digital currency-based international settlements. Additionally, it provides a customizable web and mobile user interface that enhances accessibility and user experience. By promoting interoperability between various mobile wallets and services, Almond Fintech aims to streamline currency exchange and payment processes for individuals and businesses alike.

Ieso Digital Health Ltd. is a provider of online, evidence-based mental health therapy, focusing on cognitive behavioral therapy (CBT) delivered through a digital platform. The company offers one-to-one therapy sessions for various mental health issues, including anxiety, depression, and phobias, as well as support for chronic physical health problems and cognitive impairments. Ieso's innovative approach combines proprietary technology with natural language processing and artificial intelligence to enhance therapy delivery through real-time monitoring and assessment. This enables therapists to provide effective care in a virtual environment, allowing patients to access support at their convenience. Serving a diverse clientele that includes health providers, private individuals, and businesses, Ieso aims to transform mental healthcare by making it more accessible and scalable. Founded in 2000 and based in Swavesey, United Kingdom, Ieso was previously known as PsychologyOnline.co.uk Limited before rebranding in 2015.

Ieso Digital Health Ltd. is a provider of online, evidence-based mental health therapy, focusing on cognitive behavioral therapy (CBT) delivered through a digital platform. The company offers one-to-one therapy sessions for various mental health issues, including anxiety, depression, and phobias, as well as support for chronic physical health problems and cognitive impairments. Ieso's innovative approach combines proprietary technology with natural language processing and artificial intelligence to enhance therapy delivery through real-time monitoring and assessment. This enables therapists to provide effective care in a virtual environment, allowing patients to access support at their convenience. Serving a diverse clientele that includes health providers, private individuals, and businesses, Ieso aims to transform mental healthcare by making it more accessible and scalable. Founded in 2000 and based in Swavesey, United Kingdom, Ieso was previously known as PsychologyOnline.co.uk Limited before rebranding in 2015.

Generate Biomedicines, Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on developing innovative therapies through its unique platform. The company specializes in Generative Biology, a machine learning-driven approach that analyzes known proteins to understand the relationship between genetic sequences, protein structure, and function. This enables the creation of novel therapeutic proteins, including antibodies, enzymes, and receptors, which are designed to interact specifically and effectively with various therapeutic targets. Founded in 2018 and rebranded from Generate Biologics in 2020, Generate Biomedicines aims to streamline the drug discovery process by generating new biological molecules with significant therapeutic potential.

Geneoscopy, LLC, based in Saint Louis, Missouri, specializes in developing non-invasive diagnostic tests aimed at preventing, detecting, and guiding treatment for gastrointestinal diseases, particularly colorectal cancer. Founded in 2015, the company utilizes a proprietary platform that extracts stool-derived eukaryotic RNA (seRNA) to create a multi-target RNA biomarker panel. This innovative approach allows for the identification of colorectal cancer by capturing the effects of DNA mutations associated with the disease. Geneoscopy's technology not only enhances screening compliance but also facilitates the early detection of colorectal neoplasms, ultimately aiming to reduce morbidity and mortality linked to colorectal cancer. The company is also exploring additional applications of its technology for related gastrointestinal conditions.

For over a decade, CloudMosa has been a pioneer in providing remote browser solutions for users in both the consumer and enterprise sector. We used this same technology to develop Puffin, a secure browser product lineup with a proven track record of over 150 million downloads to date. Our products are engineered to meet the strictest cybersecurity standards against zero-day threats. We strive to provide unparalleled security, speed, and efficiency for our clients. We aim to continue developing innovative products for both individual consumers and businesses alike with our years of expertise. The company was founded in 2009 and headquartered in Cupertino, California, USA.

Block Renovation is a home renovation platform that integrates design, construction labor, and materials to create a seamless renovation experience for homeowners and contractors. Founded by Koda Wang and Luke Sherwin, the company aims to simplify the often complex and confusing process of home renovations. By bringing design, sourcing, and project management together, Block Renovation provides homeowners with clarity on outcomes, quality, pricing, and timelines. This approach not only enhances the experience for homeowners looking to improve their living spaces but also offers a more efficient working method for contractors.

DeepCure Inc. specializes in drug discovery services powered by artificial intelligence. The company employs advanced algorithms for De-novo Lead Discovery, which analyzes drug candidates from a virtual library, and utilizes AI-driven Lead Optimization to enhance drug development processes. Additionally, DeepCure's proprietary database, MoIDB, is designed to maximize the scale, diversity, and synthesizability of the chemical search space. Founded in 2018 and based in Boston, Massachusetts, DeepCure aims to accelerate the development of innovative, first-in-class precision therapeutics that address unmet medical needs. The company combines deep learning algorithms with cloud computing to improve pre-clinical drug development, ultimately assisting scientists and healthcare professionals in creating more effective therapeutic molecules for various disease targets.

Robigo is a biomanufacturing company focused on developing precision microbial treatments aimed at enhancing plant health and recovering lost agricultural yields. By leveraging microbial engineering and data science, Robigo creates sustainable crop protection solutions that are designed to be more effective and safe for beneficial microbes, pollinators, humans, and the environment. This innovative approach enables farmers to improve their productivity and profitability while promoting sustainable farming practices.

Huckleberry makes behavioral expertise accessible and affordable to all families by combining AI with human experts, starting with children's sleep.

EasyExpunctions.com is a legal platform that offers a cost-effective solution for individuals seeking to erase their criminal records without the need for an attorney. The service employs a unique, patent-pending process that sets it apart from other legal software providers. By focusing exclusively on generating legal documents for reputation management, EasyExpunctions allows users to navigate the expunction process efficiently and affordably. This innovative approach empowers individuals to manage their legal records independently, eliminating the high costs associated with traditional legal services.

Kappa Pay is a fintech platform that utilizes blockchain technology to streamline payment processes for both local and cross-border transactions. The company aims to provide an affordable and reliable solution for individuals and merchants, facilitating seamless payments that resemble the simplicity of sending a message. By focusing on removing friction and barriers in financial transactions, Kappa enables users to send and receive money globally with higher transaction limits, enhancing the overall efficiency of the payment experience.

BetterUp Inc. is a leadership development company that offers an innovative online platform aimed at enhancing the personal and professional growth of individuals and organizations. Founded in 2013 and headquartered in San Francisco, BetterUp specializes in virtual coaching, providing users with personalized guidance through one-on-one sessions with a network of over 3,000 coaches available in 46 languages across more than 90 countries. The platform focuses on fostering mental fitness, career and leadership development, and social connection, thereby enabling employees to develop new behaviors and skills that promote high performance in a rapidly changing work environment. With a client base that includes prominent organizations such as NASA, Google, and Hilton, BetterUp has established itself as a leader in the field of mental health and coaching. The company is supported by a distinguished Science Board composed of experts in positive psychology and human performance, further enhancing its credibility and impact in the industry.

Exo Therapeutics, Inc. is a drug discovery and development company focused on addressing intractable pharmaceutical targets. Founded in 2018 and based in Cambridge, Massachusetts, the company utilizes its proprietary ExoSight platform to develop a pipeline of drug candidates. These candidates are designed to bind to exosites and unique binding pockets, allowing for the reprogramming of enzyme activity to achieve targeted therapeutic effects. This innovative approach aims to provide robust treatments in areas such as oncology and inflammation, while also minimizing potential side effects for patients. By employing a precise and selective methodology, Exo Therapeutics is positioned to unlock new therapeutic possibilities for a variety of diseases.

Angitia Biopharmaceuticals is a global biotechnology company dedicated to discovering and developing innovative therapeutics for serious musculoskeletal diseases. The company focuses on researching and creating breakthrough therapies aimed at treating conditions affecting bones, muscles, and joints. By prioritizing the development of novel drugs, Angitia Biopharmaceuticals aims to improve patient outcomes and facilitate recovery from severe musculoskeletal ailments.

HOMEE, Inc. is a technology company based in Tampa, Florida, founded in 2017. It offers a mobile application that connects homeowners, renters, and property managers with skilled service providers such as handymen, plumbers, electricians, and HVAC technicians. The platform facilitates both scheduled and emergency home service transactions, making it easier for users to find and hire the necessary services. Additionally, HOMEE provides tools that enhance the claims process for insurers and policyholders by connecting them with service providers, thereby streamlining emergency mitigations and repairs. Through its integrated platform, HOMEE aims to improve the efficiency of the claims service process and enhance user satisfaction.

Semios specializes in providing crop management solutions for the agricultural industry. It offers a proprietary system of in-crop wireless networks coupled with remote sensors, pest monitoring, and variable rate biological pest control. This information is provided to the grower in an interface that allows the grower to reduce agricultural inputs and increase the quality of the crop produced. The company was founded in 2010 and is headquartered in Vancouver, British Columbia.

Alamar Biosciences, founded in 2018 and based in Fremont, California, specializes in developing advanced technologies for the early detection and treatment of cancer and other diseases. The company focuses on a precision proteomics platform that enhances protein analysis and the diagnosis of various diseases through innovative antibody technologies. By facilitating the discovery of new biomarkers, Alamar aims to empower healthcare providers to identify diseases at an early stage, thereby improving potential treatment outcomes and patient care.

OptoGlo is a product development company specializing in innovative light and color display technologies. It focuses on creating advanced optical solar signs that combine backlit illumination with solar-powered energy, offering enhanced visibility for advertising and event promotions both day and night. The company utilizes nanotechnology to produce transparent illumination and ultra-high-definition displays, positioning itself as a leader in the industry. In addition to product development, OptoGlo licenses intellectual property and collaborates with partners to establish product distribution companies, expanding the reach of its cutting-edge solutions.

MedRhythms Inc. is a neuro-rehabilitation company that specializes in neurologic music therapy, employing sensors, music, and artificial intelligence to create evidence-based interventions. Founded in 2013 and based in Boston, Massachusetts, MedRhythms aims to assist individuals affected by conditions such as traumatic brain injury, stroke, Parkinson's disease, and Huntington's disease. The company's approach focuses on the intersection of music, neuroscience, and technology, developing programs to enhance sensorimotor, speech, language, and cognitive functions. By utilizing innovative methodologies, MedRhythms enables patients to leverage music as a therapeutic tool to stimulate brain activity and improve their walking and functional outcomes.

Amylyx Pharmaceuticals develops innovative therapies for Amyotrophic Lateral Sclerosis (ALS) and other neurodegenerative diseases. The company's primary product, AMX0035, is an investigational therapy that combines two active compounds, sodium phenylbutyrate and Taurursodiol. This fixed-dose formulation aims to address mitochondrial energy crises and the accumulation of toxic proteins in the endoplasmic reticulum, which contribute to neurological decline. In addition to ALS, Amylyx's research pipeline includes potential treatments for Wolfram syndrome and Alzheimer's disease. Founded in 2013 and based in Cambridge, Massachusetts, Amylyx Pharmaceuticals is dedicated to advancing solutions for serious brain disorders.

Block Renovation is a home renovation platform that integrates design, construction labor, and materials to create a seamless renovation experience for homeowners and contractors. Founded by Koda Wang and Luke Sherwin, the company aims to simplify the often complex and confusing process of home renovations. By bringing design, sourcing, and project management together, Block Renovation provides homeowners with clarity on outcomes, quality, pricing, and timelines. This approach not only enhances the experience for homeowners looking to improve their living spaces but also offers a more efficient working method for contractors.

Fount Bio is a life science company based in Cambridge, Massachusetts, focused on enhancing skin health through innovative glycopolymer research. Founded in 2018, the company develops topical products that create a long-lasting hyaluronic acid network within the skin. By addressing the delivery and biostability challenges associated with traditional formulations, Fount Bio aims to maximize the benefits of hyaluronic acid without the need for invasive injections. Its proprietary technologies are designed to support clients in creating effective skincare solutions that improve both the health and beauty of the skin.

Linus Health, Inc. is a digital health company based in Waltham, Massachusetts, founded in 2019. It specializes in developing a brain health monitoring platform that utilizes digital screening technology to enhance the assessment and treatment of cognitive and mental health. The platform collects various digital measurements, including voice, speech, gait, cognition, and eye movement, aimed at early detection and diagnosis of brain health issues. Additionally, Linus Health provides clinical decision support and care planning tools, enabling healthcare providers to offer actionable recommendations based on the insights gathered. The company's mission focuses on transforming brain health, making it accessible to individuals worldwide.

Triastek Co. Ltd., established in 2015 and headquartered in Nanjing, China, specializes in the manufacturing of 3D printed pharmaceuticals and related medical equipment. The company offers a range of drugs, including blockbuster and orphan drugs, along with complex drug delivery technologies. Triastek's portfolio comprises drug 3D printing services, such as formulation design, 3D printing equipment, and drug product development methods, with patents secured in key global markets like China, the US, Europe, and Japan. Notably, Triastek owns the Melt Extrusion Deposition (MED) technology, a universally applicable 3D printing method for solid formulations. The company's mission is to revolutionize drug delivery, development, and manufacturing through its innovative 3D printing technology.

Alentis Therapeutics AG is a clinical-stage biopharmaceutical company based in Basel, Switzerland, focused on developing innovative therapies for advanced liver diseases, including liver fibrosis, cirrhosis, and liver cancer. Established in 2019, Alentis is recognized for its pioneering work in targeting CLDN1+ cancers through the use of anti-CLDN1 antibody-drug conjugates and other therapeutic modalities. The company's research platform incorporates clinically relevant read-outs and single-cell RNA sequencing of patient liver tissues, which aids in understanding and treating fibrotic diseases. Alentis aims to modify and reverse disease progression, ultimately addressing significant health challenges associated with liver-related conditions.

Stealth BioTherapeutics is a clinical-stage biotechnology company dedicated to the discovery, development, and commercialization of therapies targeting diseases linked to mitochondrial dysfunction. Founded in 2006 and based in George Town, Cayman Islands, the company is advancing its lead product candidate, Elamipretide, which aims to address both rare genetic and age-related mitochondrial diseases. Additionally, Stealth BioTherapeutics is developing SBT-20, a small peptide that stabilizes mitochondrial structure and function during oxidative stress, and SBT-272, a compound under evaluation for rare neurodegenerative diseases, including amyotrophic lateral sclerosis. Mitochondria play a crucial role in energy production and overall organ function, making the company's focus on these organelles significant in the biopharmaceutical landscape.

Coin Metrics Inc. is a provider of blockchain and cryptocurrency data analytics, based in Cambridge, Massachusetts. Founded in 2017, the company specializes in delivering market and network data, analytics, and research to various industries and institutions involved in crypto-assets. Its offerings include the CM Network Data Pro, which provides comprehensive historical data on top cryptocurrency assets, and the CM Market Data Feed, which standardizes trade, candle, and order book data from multiple exchanges. Additionally, Coin Metrics offers CM Reference Rates, which present fixed asset pricing in U.S. dollars. By focusing on transparency and actionable data, Coin Metrics aims to empower individuals and organizations to make informed financial decisions related to cryptocurrencies.

Nebula Microsystems delivers intelligent and high-performance Analog Products for a wide variety of applications including communication, consumer, industrial, healthcare, and automotive. Power converters, high-speed SERDES, high-performance amplifiers, data converters, and high-power density DC-DC and AC-DC products are among the products offered by Nebula Microsystems.

Catalant is a Boston-based software company that specializes in strategy execution solutions for global enterprises. Founded in 2013, the company's platform enables businesses to break down strategic objectives, access and deploy resources, collaborate on execution, measure value, and continuously improve processes. Catalant's network comprises over 65,000 experts and 1,000 firms, serving more than 30% of the Fortune 100.

Endolytix is a biotech company focused on developing novel therapeutics to combat antibiotic-resistant infections, particularly those caused by non-tuberculous mycobacteria (NTM). The company aims to provide effective treatments that can eliminate pathogenic bacteria, including multidrug-resistant strains, thereby addressing significant challenges in the healthcare sector related to difficult-to-treat infections. By targeting intrinsic antibiotic resistance, Endolytix seeks to enhance the available therapeutic options and improve patient outcomes in cases where traditional antibiotics are ineffective.

Apnimed, Inc. is a clinical-stage company based in Cambridge, Massachusetts, focused on developing innovative pharmacologic therapies for sleep apnea and related disorders. Founded in 2017, Apnimed aims to address the underlying neurobiological mechanisms that contribute to obstructive sleep apnea (OSA), a serious condition affecting over 20 million Americans. Current treatments, such as CPAP devices and surgical options, primarily manage symptoms rather than the root causes of the disorder. Apnimed's therapeutics are designed to provide a simple, safe, and effective oral treatment that targets both the physiological and symptomatic effects of OSA, offering a potential alternative to existing interventions.

Stavvy, Inc. is a financial technology company based in Boston, Massachusetts, that specializes in a digital mortgage vendor platform aimed at transforming the lending experience. Founded in 2018 and originally named Stavros Technologies, the company provides tools such as Stavvy Connect, which facilitates secure communication and access to vendor data for mortgage banking professionals during the underwriting and settlement processes. Additionally, Stavvy Notarize enables title agents, lawyers, and notaries to conduct virtual closings and meetings in real-time using web conference technology. By eliminating paper-based processes and enhancing communication, Stavvy aims to improve operational efficiency while minimizing risk for its users in the mortgage industry.

PhoreMost Limited is a drug discovery company based in Cambridge, United Kingdom, focused on identifying new druggable targets for cancer and other unmet diseases. Since its incorporation in 2014, the company has developed Site-Seeker, a platform that uncovers cryptic druggable sites within the human genome and connects them to therapeutic functions in live-cell contexts. This innovative approach allows PhoreMost to design small molecule drugs based on functionally validated protein fragments. By collaborating with a global network of academic and industrial partners, the company aims to bring novel targeted therapies to market more efficiently, ultimately benefiting patients through cost savings and the development of first-in-class drug discovery programs for potential licensing to pharmaceutical companies.

Arctic Vision is a clinical-stage specialty ophthalmology company based in China, focused on developing innovative therapies to address unmet clinical needs in the treatment of ophthalmic diseases. The company boasts a portfolio of breakthrough technologies aimed at providing effective solutions for patients with rare eye conditions. Founded by prominent life sciences investors, Arctic Vision is led by an experienced team of industry veterans skilled in research and development as well as the commercialization of eye care products. Its commitment to advancing ophthalmic medicine positions it as a key player in both the Asian and global markets.

Monument Bank, established in 2017 and located in London, United Kingdom, is a commercial bank that serves mass affluent clients, including professionals, property investors, and entrepreneurs. The bank specializes in providing savings accounts and a variety of property loans, including buy-to-let loans and bridging loans. Monument is focused on delivering tailored financial services to meet the needs of its members, positioning itself as a trusted partner for individuals seeking to manage their wealth and investment opportunities effectively.

Zhishan Weixin Biotechnology integrates gene-drug research and development to treat genetic and neurodegenerative diseases. The company focuses on the research and development and subversive production of rAAV gene drugs. Zhishan Weixin's therapeutic areas cover blood diseases, rare diseases, and other disease areas.

Rockley Photonics Limited is a London-based company founded in 2013 that specializes in silicon photonics for various applications. The company develops a comprehensive range of photonic integrated circuits, sensors, and full-stack solutions aimed at high-volume markets. Rockley's technology is designed for next-generation sensing platforms, including mobile health monitoring and machine vision, as well as for high-speed data communications. By focusing on integrated optical modules, supporting electronics, software, and AI platforms, Rockley aims to establish a strong presence in dynamic and rapidly growing sectors. The company envisions photonics becoming as ubiquitous as microelectronics, leveraging its versatile platform to address diverse market needs.

Innodem Neurosciences, founded in 2016 and based in Outremont, Canada, specializes in developing artificial intelligence-driven mobile software technology focused on enhancing communication for paralyzed and intubated patients through eye movements. The company's flagship product, Pigio, utilizes eye-tracking technology to facilitate interaction between patients and caregivers. Additionally, Innodem's technology serves as a digital biomarker tool for diagnosing neurodegenerative diseases, enabling healthcare professionals to identify abnormalities, monitor disease progression, and evaluate treatment effectiveness. By providing patient self-testing capabilities, the company aims to improve the overall quality of life for patients and support clinicians in delivering more effective healthcare.

NewAmsterdam Pharma, established in 2019 and headquartered in Naarden, the Netherlands, is a late-stage biopharmaceutical company dedicated to improving patient care in cardio-metabolic disease populations. The company's primary focus is the development of transformative therapies, with its lead product, obicetrapib, being a next-generation, oral, low-dose CETP inhibitor designed to lower LDL-C levels more effectively than current treatments, particularly for patients with statin intolerance or Arteriosclerotic Cardiovascular Disease/Familial Hypercholesterolemia (ASCVD/FH) on maximally-tolerated statin therapy.

30 Technology is a biopharmaceutical platform developer focused on enhancing the lives of patients with serious and life-threatening medical conditions. The company's platform leverages the potential of nitric oxide to create new models of care, facilitating the development of innovative treatments. By doing so, it enables healthcare professionals to improve patients' healing processes and bolster their defense mechanisms against various medical challenges.

Curai Health is a virtual care company founded in 2017 by Neal Khosla and Xavier Amatriain, headquartered in Palo Alto. The company leverages artificial intelligence to provide chat-based primary care services, aiming to make high-quality and affordable healthcare accessible to everyone, anytime. Curai Health's platform integrates clinicians with advanced AI and machine learning tools to create a learning healthcare system that enhances the efficiency and cost-effectiveness of medical care. By facilitating better communication between patients and healthcare professionals, the platform aids in accurate diagnosis and treatment. Curai Health offers its services directly to consumers and through partnerships with enterprises.

DEEPEXI, officially known as Beijing Dip Technology Co., Ltd., is a prominent player in the digital transformation sector for enterprises. Established in May 2018 and headquartered in Beijing, the company has grown to employ around 160 staff members, with significant research and development capabilities concentrated in its branches across major cities like Guangzhou, Shenzhen, Nanjing, and Chengdu. DEEPEXI specializes in providing scalable business intelligence services that leverage a cloud-native Internet framework, integrating advanced technologies such as 5G, IoT, big data, AI, and cloud computing. This enables businesses to enhance their decision-making and strategic initiatives through data intelligence. The company prides itself on having a highly skilled R&D team, which includes leading experts in artificial intelligence and open-source projects.

Tallac Therapeutics is a biopharmaceutical company based in Burlingame, California, focused on developing innovative immunotherapies for cancer patients. Established in 2018, the company specializes in creating conjugates of antibodies combined with potent toll-like receptor agonists. This approach aims to activate the immune system in a targeted manner, enhancing both innate and adaptive immunity to effectively combat various solid tumor malignancies. By providing advanced treatment options, Tallac Therapeutics seeks to improve patient outcomes in the fight against cancer.

Neuroelectrics is a digital brain health company founded in 2012 and headquartered in Barcelona, Catalonia. It specializes in the development of non-invasive, high-definition electrical brain stimulation technology, including wireless EEG and various stimulation devices such as tDCS, tACS, and tRNS, which feature up to 32 channels. The company's products aim to monitor and enhance brain health by measuring and modifying brain function, thereby enabling healthcare professionals to restore brain health, reduce disabilities, and improve the quality of life for patients. In addition to its hardware offerings, Neuroelectrics also provides software and research services that support personalized neuromodulation.

CellCentric Ltd. is a biotechnology company based in Cambridge, United Kingdom, focused on developing innovative cancer therapeutic products. Established in 2003, the company specializes in small-molecule inhibitors that target p300 and CBP proteins, as well as a deubiquitinase enzyme closely linked to prostate cancer. This enzyme modulates the androgen receptor pathway, which is critical in addressing resistance mechanisms encountered with existing prostate cancer treatments. CellCentric's therapies aim to treat various cancers, including castrate-resistant prostate cancer, lung cancer, bladder cancer, non-small cell lung cancer, breast cancer, and colon cancer. By targeting specific pathways and mechanisms, CellCentric seeks to provide effective treatment options for patients with challenging cancer types.

InCarda Therapeutics is a clinical-stage biopharmaceutical company based in Newark, California, focused on developing innovative therapies for cardiovascular diseases. The company specializes in an inhaled drug delivery system aimed at treating acute paroxysmal atrial fibrillation, allowing patients to administer treatment quickly during the onset of symptoms. Its lead product, InRhythm, is an inhaled formulation of an antiarrhythmic medication designed to provide rapid relief from arrhythmic events. This method allows for effective medication delivery directly to cardiac tissue, which enhances treatment efficacy and simplifies the management of atrial arrhythmias. InCarda Therapeutics has completed Phase 1 clinical trials and is progressing through Phase 2 with its lead product.

Revolo Biotherapeutics specializes in developing innovative therapies aimed at treating autoimmune and allergic diseases by resetting the immune system for long-term disease remission. Founded in 2011 and previously known as Immune Regulation, the company focuses on creating anti-inflammatory peptides that offer significant advancements in the management of moderate to severe chronic inflammatory conditions. These peptides have the potential to modify disease progression and promote remission, providing improved treatment options for patients suffering from conditions such as asthma, atopic dermatitis, and inflammatory bowel diseases. By achieving effective long-term outcomes with less frequent dosing and without suppressing the immune system, Revolo Biotherapeutics aims to transform the landscape of immuno-inflammatory disease treatment.

Lele Ketang is an online education platform based in Beijing, China, founded in 2014. The company specializes in K-12 education, focusing primarily on primary school subjects such as math and language. Lele Ketang offers a variety of online training courses designed for primary and secondary school students, featuring three-minute video lectures and gamification elements to enhance the learning experience. Additionally, the platform provides one-on-one learning opportunities, allowing for personalized instruction tailored to individual student needs.

Prescryptive Health, Inc. is a digital health company that operates a prescription benefits platform aimed at enhancing the accessibility and affordability of medications for both payers and patients. Established in 2017 and based in Redmond, Washington, the company provides services that include analyzing current plan designs, recommending new plans, and facilitating member enrollment. Its platform empowers users by offering direct access to market pricing, unbiased information, and real-time cost insights regarding prescribed treatments. This includes details on insurance coverage, out-of-pocket expenses, and available lower-cost alternatives. Prescryptive Health serves a diverse range of clients, including employers, health plans, providers, pharmacies, and pharmaceutical companies, with the goal of democratizing the prescription drug market.

F2G Ltd is a biotechnology company based in Manchester, United Kingdom, that specializes in developing innovative therapies for serious fungal diseases. Established in 1998, F2G focuses on its F3 series of antifungal compounds, particularly targeting challenging fungi such as Aspergillus and other filamentous molds that pose significant health risks. The company leverages its proprietary genomics technology, MycoBank, to identify critical gene targets in fungi, facilitating the creation of effective antifungal agents. Since its initial funding in 2002, F2G has expanded its research and development capabilities, enabling it to advance its patented compounds and contribute to addressing life-threatening fungal infections that affect individuals with compromised immune systems.

Vesigen Therapeutics, established in 2020 and based in Cambridge, Massachusetts, specializes in developing innovative therapeutic products. The company's core technology, ARMMs (ARRDC1 Mediated Microvesicles), facilitates the delivery of various payloads such as RNAs, proteins, and gene-editing complexes directly into the cytoplasm of target cells. This approach overcomes intracellular delivery barriers, expanding the scope of treatable conditions and enabling the development of novel therapies for unmet medical needs.

Arctic Vision is a clinical-stage specialty ophthalmology company based in China, focused on developing innovative therapies to address unmet clinical needs in the treatment of ophthalmic diseases. The company boasts a portfolio of breakthrough technologies aimed at providing effective solutions for patients with rare eye conditions. Founded by prominent life sciences investors, Arctic Vision is led by an experienced team of industry veterans skilled in research and development as well as the commercialization of eye care products. Its commitment to advancing ophthalmic medicine positions it as a key player in both the Asian and global markets.

neoX BIOTECH is a biotechnology company established in 2018 and located in Beijing, China. The company specializes in the development of antigen-based cancer vaccines, leveraging a combination of artificial intelligence and biophysics to enhance drug research and development. neoX BIOTECH has created a neoantigen prediction and TCR screening platform that facilitates the discovery of effective macromolecular and multispecific drugs, particularly within the immuno-oncology sector. By characterizing protein-protein interactions, the company aims to advance early therapeutic discovery, ultimately improving treatment options for cancer patients.

Amylyx Pharmaceuticals develops innovative therapies for Amyotrophic Lateral Sclerosis (ALS) and other neurodegenerative diseases. The company's primary product, AMX0035, is an investigational therapy that combines two active compounds, sodium phenylbutyrate and Taurursodiol. This fixed-dose formulation aims to address mitochondrial energy crises and the accumulation of toxic proteins in the endoplasmic reticulum, which contribute to neurological decline. In addition to ALS, Amylyx's research pipeline includes potential treatments for Wolfram syndrome and Alzheimer's disease. Founded in 2013 and based in Cambridge, Massachusetts, Amylyx Pharmaceuticals is dedicated to advancing solutions for serious brain disorders.

Big Health is a digital therapeutics company headquartered in London, United Kingdom, that specializes in developing and marketing innovative behavioral health programs. The company's flagship product, Sleepio, is a digital sleep improvement program that employs Cognitive Behavioral Therapy techniques to address and personalize sleep disorders. By offering a fully automated healthcare portal, Big Health delivers highly personalized digital therapeutics and behavioral programs aimed at tackling various mental health issues. Their approach combines medical consultation with user-friendly technology, enabling individuals to effectively manage and overcome sleep-related disorders in an efficient manner.

Prilenia is a clinical-stage biotechnology company focused on developing innovative treatments for neurodegenerative and neurodevelopmental disorders. Founded in 2018, the company operates from locations in Israel, the Netherlands, and Boston. Its primary asset is Pridopidine, an oral drug candidate that has demonstrated an established safety profile and shows promise in treating various movement disorders and neurodegenerative diseases in both adults and children. Prilenia aims to enhance the functional capacity of patients, particularly those undergoing early hemodialysis, by addressing the underlying challenges posed by these conditions.

Heyuan Biotechnology is a biotechnology company focusing on the field of gene therapy services. They offer gene therapy vectors, gene function research, drug targets, and efficacy for the basic research of gene therapy research, among other services.